Aldeyra Therapeutics, Inc. (ALDX) Earnings

Aldeyra Therapeutics, Inc. is expected to report next earnings on August 6, 2026 (in NaN days), with a consensus EPS estimate of $-0.11. ALDX has beaten EPS estimates in 8 of its last 12 reported quarters (average surprise +33.3% over the last four).

Next earnings
Aug 6, 2026in NaN days
EPS est $-0.11 · Revenue est $31M
Track record
Beat EPS in 8 of 12 quarters
Avg surprise +33.3% (last 4 quarters)
Earnings history
Report dateEPS estEPS actualSurpriseRevenueRev. surprise
May 7, 2026$-0.13$-0.06+53.8%
Nov 5, 2025$-0.17$-0.13+23.5%
Aug 7, 2025$-0.21$-0.16+23.8%
May 14, 2025$-0.25$-0.17+32.0%
Feb 28, 2025$-0.25$-0.27-8.0%$244526
Nov 7, 2024$-0.25$-0.25+0.0%
Aug 1, 2024$-0.14$-0.28-100.0%
May 2, 2024$-0.08$-0.14-75.0%
Mar 7, 2024$-0.21$-0.08+61.9%$392620-86.9%
Nov 3, 2023$-0.24$-0.14+41.7%
Aug 3, 2023$-0.31$-0.15+51.6%
May 4, 2023$-0.30$-0.27+10.0%

Source: company filings + earnings calendar. For informational purposes only — not investment advice.

Earnings call summary

Q4 FY2022 · March 9, 2023

AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.

Management highlights

• Achieved two FDA accepted new drug applications: Reproxalap for dry eye disease and ADX-2191 (priority review for primary vitreoretinal lymphoma). • Focused on advancing next-generation RASP modulation platform: ADX-629, ADX-246, and ADX-248 in 2023. • ADX-629 in Phase 2 trials for indications like idiopathic nephrotic syndrome, Sjogren-Larsson syndrome, and atopic dermatitis; top-line results expected in second half of 2023. • Planned Phase 2 trial in moderate alcohol-associated hepatitis; top-line results expected for refractory/chronic cough trial in first half of 2023. • ADX-2191 NDA priority review for ocular lymphoma (PDUFA June 21, 2023); PDUFA for Reproxalap is November 23, 2023; ongoing partnering discussions for Reproxalap; Reproxalap showed superior visual acuity in dry eye safety trial. • Commercial preparations for Reproxalap and ADX-2191, with ADX-2191 targeting retinal surgeons and Reproxalap targeting optometrists.

Guidance

• Cash, cash equivalents, and marketable securities as of December 31, 2022 were $174.3 million, sufficient to fund operating expenses into the second half of 2024. • PDUFA dates: Reproxalap on November 23, 2023; ADX-2191 on June 21, 2023. • Top-line results expected for ADX-629 trials (Sjogren-Larsson syndrome, atopic dermatitis, idiopathic nephrotic syndrome), INVIGORATE-2 trial, and Phase 2 trial of ADX-2191 in retinitis pigmentosa in 2023.

Risks & headwinds

• Risks that clinical trial results may not predict future trial outcomes accurately. • Regulatory risks associated with FDA review and approval processes for NDAs. • Uncertainties in partnering discussions and commercialization of products like Reproxalap.

Analyst Q&A

  • Q: Marc Goodman asks about the side effect profile of oral products.

    A: Todd Brady discusses RASP modulation's safety, noting ADX-629 has very few side effects and that RASP modulation avoids toxicity by influencing a family of mediators, not individual proteins.

  • Q: Yigal Nochomovitz inquires about Reproxalap partnering discussions and the AC trial.

    A: Todd Brady mentions robust partnering conversations for Reproxalap, highlights Reproxalap's differentiators in dry eye, and discusses the AC trial's overlap with dry eye and potential impact on partnering decisions.

  • Q: Justin Kim asks about ADX-246 differentiation.

    A: Todd Brady talks about ADX-246's potency and potential once-daily dosing, distinguishing it from ADX-629 which is administered twice daily.

  • Q: Sung asks about ADX-2191 priority review impact and visual acuity strategy.

    A: Todd Brady explains regulatory strategy of submitting NDA for ocular lymphoma first, and discusses how visual acuity data from Reproxalap's safety trial will be highlighted in label negotiations.

  • Q: Catherine Novack asks about visual acuity change in Reproxalap's safety trial and RASP modulators in geographic atrophy.

    A: Todd Brady notes Reproxalap's visual acuity improvement was statistically significant vs. vehicle, and discusses RASP modulation's dual mechanism in geographic atrophy (anti-inflammatory and preventing metabolite accumulation).

  • Q: Yale Jen asks about INVIGORATE-2 study status and retinitis pigmentosa data.

    A: Todd Brady discusses INVIGORATE-2 enrollment nearing completion and the significance of retinitis pigmentosa trial as a milestone for ADX-2191